The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

BACKGROUND: Homocysteine has been postulated as a novel, potentially reversible risk factor for osteoporosis and related fractures. We evaluated whether homocysteine-lowering therapy with B-vitamins in patients with symptomatic cerebrovascular disease reduced the incidence of osteoporotic fractures....

Descripción completa

Detalles Bibliográficos
Autores principales: Gommans, John, Yi, Qilong, Eikelboom, John W, Hankey, Graeme J, Chen, Christopher, Rodgers, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848681/
https://www.ncbi.nlm.nih.gov/pubmed/24004645
http://dx.doi.org/10.1186/1471-2318-13-88

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848681/
https://www.ncbi.nlm.nih.gov/pubmed/24004645
http://dx.doi.org/10.1186/1471-2318-13-88

Ejemplares similares